OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Neurology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Transmembrane protein interacts with α-synuclein to confer risk of PD	448
Lymphatic propagation of α-synuclein	440
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma	344
Brain stimulation aids walking after spinal injury	332
Reply to ‘Perils and pitfalls of near-death experience research’	327
ANA2025 marks important milestones for the ANA and NINDS	314
Genetic insights from Parkinson disease in African and African admixed populations	308
Nociceptive action of calcitonin gene-related peptide in the trigeminovascular system	271
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications	268
Neural cell state shifts and fate loss in ageing and age-related diseases	265
Global synergistic actions to improve brain health for human development	225
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms	217
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking	201
Disease-specific modifications of tau protein	197
Continuous levodopa production by an artificial enzyme	183
TREM2 mediates phagocytosis in glioblastoma	178
SEQUINS — a new initiative to address disparities in neurology	172
Nir Giladi (1955–2024)	165
Spinal muscular atrophy treatment in utero	158
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause	155
The Digitized Memory Clinic	150
Gut macrophages involved in Parkinson disease pathogenesis	150
Mitochondrial DNA instability in Huntington disease	142
The impact of rare genetic variants on Alzheimer disease	141
Imperatives and co-benefits of research into climate change and neurological disease	134

Psychosis-causing lesions mapped to a hippocampal circuit	133
The role of the gut microbiota in multiple sclerosis	133
Ultrasound lets gene therapy into the brain	113
Brain volume is associated with cognition in MS	111
Amyloid plaques: hotspots for microglial turnover	108
Challenges of combining multimodal data in assessment of people with traumatic brain injury	105
MRI-based deep learning for TLE diagnosis	100
Gene therapy for seizures in focal cortical dysplasia	99
Neurological care for LGBT+ people	95
First trials test targeting of α-synuclein for Parkinson disease	90
The challenges of anti-tau therapeutics in Alzheimer disease	89
Author Correction: Viral pathogens increase risk of neurodegenerative disease	88
Precision neuroimmunology in multiple sclerosis — the horizon is near	86
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice	85
Management of freezing of gait — mechanism-based practical recommendations	82
Implementation of the 2024 revision of the McDonald criteria for multiple sclerosis	80
Motor neuron disease in Africa: a critical appraisal of the literature	79
α-Synuclein pathology as a target in neurodegenerative diseases	79
Neuroinflammation predicts cognitive decline in FTD	79
Parkinson disease pathology can originate in the kidney	76
Diversity, equity and inclusion in neurology	76
Food is brain medicine — relevance and translation to neurology	74
Implications of AD plasma and PET biomarker discordance	74
Neurosteroids alleviate seizures in rats	73
Glymphatic dysfunction in PD clinical progression	71
A new biological classification for Parkinson disease	69
Addressing disparities in neurology by building the workforce in LMICs	69
Ultrasound ablation treatment for PD	64
Thalamic inflammation — a therapeutic target for brain injury?	61
New IDEAS about amyloid, race and dementia disparities	61
Post-COVID dysautonomias: what we know and (mainly) what we don’t know	59
Coeliac disease as a model for understanding multiple sclerosis	59
Spinal cord stimulation for the treatment of chronic pain	58
Skull bone marrow changes in multiple sclerosis	58
Newborn screening for spinal muscular atrophy: time is motor neuron	57
Amyloid-lowering immunotherapies for Alzheimer disease: current status and future directions	56
From the prodromal stage of multiple sclerosis to disease prevention	56
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease	56
Is Alzheimer disease a disease?	56
Synaptic degeneration in Alzheimer disease	55
The global and regional burden of diabetic peripheral neuropathy	50
X-chromosome variants and PD in Latin America	50
Hypothyroidism is associated with dementia risk	49
Continuing evolution of migraine-specific therapies — targeting migraine with precision and persistence	48
Genetic susceptibility determines Epstein–Barr-virus-associated risk of multiple sclerosis	48
Neurology in 2025 — reflections from Africa	47
Oligomeric tau could spread through synapses in AD	46
Lorenzo’s House: shining a light on young-onset dementia	46
Peripheral nervous system immune-related adverse events due to checkpoint inhibition	46
Neurofilament light chain induces neuroinflammation	46

Limbic-predominant age-related TDP43 encephalopathy (LATE) neuropathological change in neurodegenerative diseases	45
Global epidemiology of migraine and its implications for public health and health policy	44
Risk locus for paediatric astrocytoma identified	44
The inter-relationship between delirium and dementia: the importance of delirium prevention	44
Moving towards meaningful patient and public engagement	42
Dual function of biomolecular condensates	39
α-Synuclein seeds in amyotrophic lateral sclerosis	38
T cells implicate Epstein–Barr virus in multiple sclerosis pathogenesis	37
CAR T cells offer hope in glioblastoma	36
Multi-ancestry GWAS identifies 16 novel Alzheimer disease risk loci	36
Prognostic plasma biomarkers for spinal cord injury	36
New developments in guidelines for brain death/death by neurological criteria	31
Reply to ‘Recalled experiences of death: need for empirical research without prejudice’	30
Promoting collaboration at the brain–heart interface	30
Neurology in 2025 — reflections from the USA	30
Reactive astrocyte biomarkers mirror Alzheimer disease pathology	29
Insights from 25 years of onabotulinumtoxinA in migraine — mechanisms and management	28
Impaired glymphatic drainage links amyloid and tau to cognitive dysfunction	28
Inflammasomes in neurological disorders — mechanisms and therapeutic potential	28
Understanding the long-term neurological effects of SARS-CoV-2 infection	28
The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology	28
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease	27
Facioscapulohumeral muscular dystrophy: the road to targeted therapies	27
Plasma extracellular vesicle biomarkers for frontotemporal dementia and related disorders	27
Huntington disease-like 2: insight into neurodegeneration from an African disease	27
ALS pathogenesis linked to actin barrier collapse	26
Origins and immunopathogenesis of autoimmune central nervous system disorders	26
BCAS1+ oligodendrocytes aid remyelination in MS	25
Author Correction: The complex aetiology of cerebral palsy	24
Urogenital dysfunction in neurological diseases	23
AI aces diagnosis of chronic ataxias	23
Pathogenetic mechanisms and treatment targets in cerebral malaria	23
Antisense oligonucleotide shows potential in Charcot–Marie–Tooth disease	23
Pharmacological rehabilitation for stroke	22
Immune gateways bypass blood–brain barrier for drug delivery in stroke	21
AI and protein structure and function in neurological disease: relevance to disease management	20
The potential of low-field MRI for global dementia care	20
Serum NfL as an MS biomarker	20
Addressing disparities in the global epidemiology of stroke	19
Effects of diet on MS onset and course	19
Molecular biomarkers for vascular cognitive impairment and dementia	19
The murky waters of sex differences in post-stroke cognitive impairment	19
Clocking the age of Parkinson disease onset	19
Nusinersen treatment response markers	18
Altered muscle cholesterol transport in ALS	17
Predictive tools in psychosis: what is ‘good enough’?	17
Nanoprobe for blood–brain barrier changes	17
Mechanistic insights into the interaction between epilepsy and sleep	16
From adaptive deep brain stimulation to adaptive circuit targeting	15
Sex and gender in neurodevelopmental conditions	15
Alzheimer disease seen through the lens of sex and gender	15
Disease-modifying therapies for Parkinson disease: lessons from multiple sclerosis	15
Advancing multiple sclerosis management in older adults	14
Multidimensional MRI detects astrogliosis	14
Markers help to predict dementia with Lewy bodies	14
Limitations of neurocentric models for near-death experiences	13
Alzheimer disease in Down syndrome linked to APOE	13
Shared glial pathology in HD and schizophrenia	13
Seizure-associated changes in the Golgi apparatus	13
Walking the Talk for Dementia — an experience to break down barriers	13
Author Correction: Why functional neurological disorder is not feigning or malingering	13